“No immunity, No life”
Our body's immune system has been essential to allow the human species to survive for so long since its emergence. Throughout history, our immune system has helped us battle infections. Now, with recent developments in molecular biology and tumor immunology, it is changing to the fight against cancer. Since 2010, many results of clinical trials proving the true efficacy of immunotherapy have been published, and a cancer treatment utilizing anti-tumor immunity, namely checkpoint inhibitors, has been developed. Continuing with this trend, "Science" magazine named cancer immunotherapy as the "Breakthrough of the year" in 2013, and gene-modified T-cell therapy using chimeric antigen receptors (CAR-T) was also designated as a "breakthrough therapy" by the U.S. Food and Drug Administration (FDA) in 2014. The immune system is steadily becoming a fundamental concept in the treatment of cancer.
Cancer has been the leading cause of death in Japan since 1981 and kills over 300,000 people per year. Currently, approximately one third of the nation is diagnosed with cancer at some stage in their lives. Standard treatments for fighting cancer are surgery, chemotherapy and radiotherapy, with other treatments becoming a possibility in the near future. Our immunity has the ability to monitor and fight cancer formed in our own bodies, and immunotherapy has the possibility to allow all the cancer patients to use their own immunity to fight against cancer. Proven to be truly effective in recent clinical trial data, cancer immunotherapy will continue to greatly support cancer patients and their fight with cancer.
Noile-Immune Biotech, Inc. was founded as a venture company holding partnership with the National Cancer Center (hereinafter referred to as "NCC"), and Yamaguchi University, to conduct research and development on cancer immunotherapy. The NCC is the largest government-established institution focusing on cancer treatment in Japan. The NCC is also an important base for the implementation of early development tests in the field of new cancer treatment, which has seen more progress in the US and Europe, and aims for global development originating in Japan. Focusing on cellular immunotherapy, a therapy gaining particular interest as the next-generation of cancer treatments, we will develop next generation of CAR-T therapy supported by those institutions.
Noile-Immune Biotech, Inc. lead the research teams that have made achievements such as those engaged in the development of checkpoint inhibitors in the US Academia, and develop many promising therapies that are yet developed or under development in conjunction with industry, government and academia.
Explore innovative cancer immunotherapy and long lasting corporate growth,
Contribute to the improvement of cancer treatment,
Bring hope and wellness to every cancer patients.